Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,340.13 -745.76 (-1.11%) CMC Crypto 200
1,426.50 +11.74 (+0.83%)
Roche Holding AG (RO.SW)
| Previous close | 244.20 |
| Open | 244.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 244.80 - 250.20 |
| 52-week range | 229.40 - 318.00 |
| Volume | |
| Avg. volume | 34,471 |
| Market cap | 186.452B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 17.48 |
| EPS (TTM) | 14.31 |
| Earnings date | N/A |
| Forward dividend & yield | 9.60 (3.93%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 263.00 |
ZacksRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
GlobeNewswireFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
